Here you can read about everything that's happening in the ISB Group.
Elin is one of the members of Swedish National Committee for the Protection of Animals used for Scientific Purposes – the 3Rs Center’s steering group. This group just finished a two days’ meeting in Jönköping focused on the business plan for 2023.
More information about the activities of the Swedish 3Rs Center.
Elin was recently awarded the prestigious AstraZeneca Science Award 2017 in the category Post-Doc. All the short-listed candidates was invited to the ceremoni with dinner at the Guildhall in the centre of the historic city of Cambridge. The top-right picture shows Elin being interviewed directly after the prize ceremony answering the typical question “how does it feel”.
Signaling to regulate FOXO1 may be the most important mechanism for
insulin to control transcription. In spite of this, little
is known about how insulin regulates FOXO1 and how
FOXO1 may contribute to insulin resistance in adipocytes, which is the
most critical cell type in the development of
insulin resistance. We report a detailed mechanistic analysis of insulin
control
of FOXO1 in human adipocytes obtained from
non-diabetic subjects and from patients with T2D.
We have had an abstract selected for an oral
presentation at the 6th Conference
on Systems Biology of Mammalian Cells in Munich. The abstract is about our
long-term work with diabetes modeling. Gunnar will hold the presentation April
8th in the session Systems Medicine &
Systems Pharmacology chaired by Werner Mewes & Frank
Lammert. We hope to see you there!
We have published an opinion paper in Interface Focus:
In the paper, we present an analysis of the current
situation where mathematical modeling steadily becomes more and more
appreciated as a tool in biomedical research and in drug development projects.
However, there are still major issues to overcome before modeling can become
one of the mainstream tools in such projects, and even more so before modeling
can be used directly in the actual treatment of patients. We review current
state-of-the-art models in diabetes research and address the most important
issues to overcome before such models can be used in drug development and in
the clinic.
We involved authors from AstraZeneca, Uppsala University,
and Eindhoven Technical University with competences reaching from disease
progression modeling, to mixed-effect PKPD modeling in the field of diabetes to
get a broad take on the subject. The paper is part of a theme issue The
Human Physiome: a necessary key to the creative destruction of medicine
organized by Stig W. Omholt and Peter Hunter from the Virtual Physiological
Human institute.
